GeneNews has signed a binding agreement with multinational private equity firm Milost Global for up to $10 million in equity and debt financing.
SOL will help Personal Genomics to further develop its research projects and implement its new facility dedicated to DNA sequencing.
Dell Technologies Capital, newly out of stealth, invested in Edico Genome because it believes whole-genome sequencing is almost ready to take off on a wide scale.
Israel-based BiomX uses a proprietary microbiome modulation technology to discover and develop microbiome-based therapeutics.
wiss genomic data management company BC Platforms seeks to add a clinical component to its existing software this year.
Sequencing IT developer Edico said it will use the funding to build out its Dragen bioinformatics processor and step up marketing efforts.
The company is developing genetic test for chronic diseases, including ones of the pancreas.
The company sells the portable Hunter Real-Time PCR instrument for DNA analysis and a portfolio of test kits for use in food safety, food fraud, and microbiologically influenced corrosion.
The firm will sell 855,000 shares of its common stock to three investors. It will also sell warrants to the same investors.
The new investment from healthcare equity firm Essex Woodlands follows a $15 million round the company closed with the same investor this summer.
Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.
The Washington Post reports that the US Department of Agriculture told its researchers to label peer-reviewed articles as "preliminary" work.
Researchers have sequenced the genomes of both the coast redwood and the giant sequoia, according to the San Francisco Chronicle.
In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.